Hype tends to precede the reality in biotech, but the reality does follow. Usually. - Arvind Gupta
Arcus Biosciences, Inc. (RCUS) is an oncology-based biopharmaceutical company working to create cancer therapies. Its pipeline contains many small molecules in phase 1 and phase 2 clinical trials. Its treatments seek to address prostate, lung, colorectal, pancreatic, and breast cancer. Specifically, the molecules AB928 and AB680 seek to counter the harmful effects of adenosine, a harmful and immunosuppressive byproduct of cancerous tumors. Molecules AB154 and Zimberelimab are designed to combat TIGIT-mediated signaling, which suppresses anti-cancer immune